A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Novartis Pharmaceuticals1 site in 1 country6,600 target enrollmentOctober 2, 2013

ConditionsAcute Heart Failure

InterventionsRLX030 Placebo

DrugsRLX030 Placebo

Overview

Phase: Phase 3
Intervention: RLX030
Conditions: Acute Heart Failure
Sponsor: Novartis Pharmaceuticals
Enrollment: 6600
Locations: 1
Primary Endpoint: Percentage of Participants With Worsening of Heart Failure (WHF) Through Day 5
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Detailed Description

This Phase IIIb outcome study in AHF patients was designed as a multicenter, randomized, double-blind, placebo-controlled, event-driven study in order to assess the efficacy, safety and tolerability of intravenous infusion of serelaxin or placebo. The AHF patients randomized to either serelaxin or placebo in the study were followed for a period of 180 days, and were required to receive standard-of-care background HF management during both the index hospitalization and post discharge according to regional or local guidelines/institutional standards.

Registry

clinicaltrials.gov

Start Date

October 2, 2013

End Date

February 1, 2017

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Novartis Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female 18 years of age, with body weight ≤160 kg
•Hospitalized for AHF with anticipated requirement of IV therapy for at least 48 hours; AHF is defined as including all of the following measured at any time between presentation (including the emergency department) and the end of screening:
•Persistent dyspnea at rest or with minimal exertion
•Pulmonary congestion on chest radiograph
•B-type natriuretic peptide (BNP) ≥500 pg/mL or N-terminal (NT)-proBNP ≥2000 pg/mL; for patients ≥ 75 years of age or with current atrial fibrillation (at the time of randomization), BNP ≥ 750 pg/mL or NT-proBNP ≥ 3,000 pg/mL
•Systolic BP ≥125 mmHg at the start and at the end of screening
•Able to be randomized within 16 hours from presentation to the hospital, including the emergency department
•Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode.

Exclusion Criteria

•Dyspnea primarily due to non-cardiac causes
•Known history of respiratory disorders requiring the daily use of IV or oral steroids (does not include inhaled steroids); need for intubation or the current use of IV or oral steroids for chronic obstructive pulmonary disease (COPD)
•Temperature \>38.5°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment
•Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment.
•AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate \<45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of \>130 beats per minute
•Patients with severe renal impairment defined as pre-randomization estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2 calculated using the Simplified Modification of Diet in Renal Disease (sMDRD) equation, and/or those receiving current or planned dialysis or ultrafiltration
•Patients with hematocrit \<25%, or a history of blood transfusion within the 14 days prior to screening, or active life-threatening GI bleeding.
•Known hepatic impairment (as evidenced by total bilirubin \> 3 mg/dL, or increased ammonia levels, if performed) or history of cirrhosis with evidence of portal hypertension such as varices.
•Significant, uncorrected, left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area \<1.0 cm2 or mean gradient \>40 mmHg on prior or current echocardiogram), and severe mitral stenosis
•Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated.

Arms & Interventions

Serelaxin (RLX030)

Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.

Intervention: RLX030

Placebo

Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.

Intervention: Placebo

Outcomes

Primary Outcomes

Percentage of Participants With Worsening of Heart Failure (WHF) Through Day 5

Time Frame: Day 5

The percentage of participants with WHF through day 5 was assessed.

Percentage of Participants With Confirmed Cardiovascular (CV) Death Through Day 180

Time Frame: 180 days

The percentage of participants with an adjudicated CV death through day 180 was assessed.

Secondary Outcomes

Change From Baseline in NT-proBNP Biomarker(Baseline, Day 2, Day 5 and Day 14)
Percentage of Participants With All-cause Death Through Day 180(180 days)
Change From Baseline in Cystatin C Biomarker(Baseline, Day 2, Day 5 and Day 14)
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization(180 days (Patients still in the hospital at Day 60 were censored at Day 60))
Change From Baseline in hsTroponin T Biomarker(Baseline, Day 2, Day 5 and Day 14)
Length of Total Hospital Stay (LOS) During the Index Acute Heart Failure (AHF) Hospitalization(180 days (Participants still in the hospital at Day 60 were censored at Day 60))
Percentage of Participants With First Occurrence of Adjudicated CV Death or Adjudicated Re-hospitalization(180 days)
Percentage of Participants With First Improvement Since Baseline in Congestive Signs and Symptoms of Heart Failure(From baseline to Day 5)